November 10th. 2021. Palobiofarma announces positive results in the Phase IIa clinical trial evaluating it´s first in class investigational treatment PBF-677 in patients with mild to moderate ulcerative colitis.
The Phase II trial studied the safety, tolerability, and preliminary efficacy of PBF-677 in patients with mild to moderate Ulcerative Colitis in flair condition on top of the standard of care Mesalazine (5-ASA). 32 patients were recruited in the trial, 22 of them received PBF-677 (200mg) +...